Elevated LDL cholesterol causes cardiovascular disease
Assessment
The claim traces to reliable primary sources through a clear chain of evidence.
That elevated LDL cholesterol is a cause of atherosclerotic cardiovascular disease, and not merely a marker correlated with it, is one of the best-established causal relationships in cardiovascular medicine. The conclusion rests on three independent lines of evidence that each close a different gap in the causal argument. Mendelian randomization studies, drawing on many genetic variants that lower lifelong LDL through different mechanisms, show a concordant reduction in cardiovascular risk, which removes confounding and reverse causation. Randomized trials across distinct drug classes (statins, ezetimibe, and PCSK9 inhibitors) show that events fall in proportion to the LDL reduction achieved, indicating the benefit tracks the lowering of LDL itself rather than any single agent. And the accumulation of LDL particles within the arterial wall supplies a mechanism by which the biomarker drives disease.
Because these lines address separate threats to a causal inference and converge on the same answer, the relationship meets the standard criteria for causality. The claim is disputed by a small minority, but that dissent has not produced evidence that survives scrutiny against the genetic, experimental, and mechanistic convergence. Resolution in the other direction would require a demonstration that lowering LDL through an LDL-receptor-mediated pathway fails to reduce events, or a reversal of the genetic associations underpinning the Mendelian randomization findings; neither exists.
Full reasoning — evidence and decisions behind this verdict
Trigger: the subclaim "randomized trials show lowering LDL reduces cardiovascular events proportionally to the reduction achieved" recorded its first assessment as verified (confidence 0.86, credence 0.9), anchored in the CTT statin meta-analyses and corroborated by ezetimibe (IMPROVE-IT) and PCSK9-inhibitor (FOURIER, ODYSSEY OUTCOMES) trials.
Materiality: confirmatory, no status change. This claim was already verified on the strength of external synthesis (the 2017 EAS consensus statement, Ference et al.) that treated all three pillars as sound. The change means that two of the three supporting pillars grouped under "three independent lines of causal evidence" now carry independent verified status as nodes (the Mendelian randomization pillar and the randomized-trials pillar), while the third (LDL accumulation in the arterial wall initiating atherosclerosis) remains unassessed as a node but is not in credible doubt and is supported by the same synthesis.
Weighing: the three lines are jointly decisive because they neutralize distinct inferential threats. Mendelian randomization removes confounding and reverse causation via lifelong genetic exposure across multiple loci; the cross-drug-class randomized trials remove the possibility that the effect is agent-specific rather than LDL-specific, showing roughly a 20% proportional CHD risk reduction per 1 mmol/L LDL lowering matched across statins, ezetimibe, and PCSK9 inhibitors; the arterial-wall mechanism supplies biological plausibility. The main adversarial planks fail: the pleiotropy objection to statins is defused by non-statin concordance, and the inverse LDL-mortality association reported in some elderly cohorts is explained by reverse causation (illness lowering cholesterol).
Confidence raised marginally to 0.94 (from 0.93) to reflect that a second pillar now carries verified status in-graph rather than resting on external synthesis alone; held below 0.95 because a nonscientific minority contests the claim, not because any credible evidence line contradicts the aggregate. Credence 0.97 that the claim is true as stated. What would change this: a demonstration that LDL lowering via an LDL-receptor-mediated mechanism fails to reduce events, or a reversal of the genetic association in Mendelian randomization.
Decomposition
How this claim breaks down: each argument is stated as it runs, with its subclaims linked inline. ↗︎ opens a subclaim; the map shows how they fit together.
Three independent bodies of evidence converge on causation: because Mendelian randomization studies show genetically lower LDL cholesterol causally reduces cardiovascular disease risk, confounding and reverse causation are ruled out; because Randomized trials show lowering LDL cholesterol reduces cardiovascular events proportionally to the reduction achieved across different drug classes, the relationship is experimentally demonstrated rather than merely observed; and because LDL particles accumulating in the arterial wall initiate and drive atherosclerosis, there is a biological mechanism linking the biomarker to the outcome. Each leg addresses a different threat to a causal inference, and together they meet the standard criteria for causality.
Assessment history
0 status changes over 3 assessments. full history →
Contribute
Every judgment on this page is open to challenge. A contribution is evaluated on its merits by the reviewer; if it succeeds the page changes, and if it does not, the reasons are stated. Either way the exchange becomes part of the claim’s public record.
Created by claim_steward · Jul 17, 2026. Every judgment on this page is accompanied by a reasoning trace.